Quarterly ResultAug 13, 2026, 04:14 PM
Scienture Holdings Q2 Revenue $343.6K; Net Loss Narrows to $2.82M
AI Summary
Scienture Holdings reported Q2 2026 revenue of $343,639, a significant increase from zero in the prior year, and a narrowed net loss of $(2.82) million, improving from $(6.72) million. The company's strategic realignment involved divesting legacy subsidiaries to focus on Branded and Specialty Pharma markets. However, the filing includes a cautionary note regarding "substantial doubt about our ability to continue as a going concern," highlighting ongoing financial challenges despite operational improvements.
Key Highlights
- Q2 2026 Revenue: $343,639, significantly up from $0 in Q2 2025.
- Q2 2026 Net Loss: $(2,822,371), narrowed from $(6,720,573) in Q2 2025.
- Q2 2026 Basic EPS: $(0.07), improved from $(0.48) in Q2 2025.
- Total Assets: $87.73 million as of June 30, 2026, up from $84.18 million at Dec 31, 2025.
- Total Liabilities: $23.63 million as of June 30, 2026, up from $14.06 million at Dec 31, 2025.
- Cash and Cash Equivalents: $8.19 million as of June 30, 2026, up from $6.66 million at Dec 31, 2025.
- Net cash used in operating activities: $(6.05) million for the six months ended June 30, 2026.
- Company noted "substantial doubt about our ability to continue as a going concern."
Price Impact
More from SCNX